AidsmapIn a study presented at this week’s Conference on Retroviruses and Opportunistic Infections (CROI 2022), a combination of two broadly neutralising antibodies (bNAbs) enabled almost half of a group of children born with HIV to maintain an undetectable viral load over a six-month period.
Dr Roger Shapiro of Harvard Medical School conducted the study in collaboration with research institutes in the US and Botswana.
The study was called ‘Tatelo’, which means ‘the next thing’ in Setswana. Shapiro said children may be an important group to treat with longer-lasting antibody-based therapies as adherence to, and the side effects of, oral antiretroviral therapy (ART) are often challenging. In addition, there is evidence that in some children treated very soon after birth, limiting the amount and diversity of proviral DNA that ends up in the ‘reservoir’ of quiescent cells could give them a better chance at controlling HIV, spontaneously or with novel medications, later in life.
Read the full story at Aidsmap.
All Aidsmap reports from CROI 2022.
SEE ALSO:
- HIV i-Base: CROI 2022: Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
- Healio: Study shows bNAbs may be viable treatment for children with HIV
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.